Plasma levels of intranasal midazolam at 0.4 mg/kg and 0.2 mg/kg doses

Z. Sayany, DMD MT. Nazif, DDS, MDS G.J. Burckart, PhD D.H. McKibben, DMD, MDS J.G. Hadeed

Midazolam has gained recent popularity in anesthesiology, pediatrics, and dentistry because of its wide margin of safety, rapid onset, anterograde amnesia, and adequate anxiolysis. Midazolam can be given intranasally, which is less invasive than intravenous administration and gives high plasma levels. Most previous reports on midazolam recommended a therapeutic dose of 0.1-0.3 mg/kg for intranasal administration to obtain adequate sedation.

The objective of this study was to compare the plasma levels of midazolam obtained from 0.2 mg/kg and 0.4 mg/kg doses given intranasally in Rhesus monkeys over a 60-min time period. The results of this study would provide the clinician with a better understanding of the plasma levels of this drug given by the intranasal route, particularly at the higher dosage.

Materials and methods

Five young adult Rhesus monkeys were included in this study. The weight of the animals ranged from 3.4 to 4.0 kg, with a mean of 3.6 kg. Each animal was restrained and anesthetized with ketamine HCl at 25 mg/kg IM. An intravenous fluid of 5% dextrose and water with 1/4 normal saline was initiated and profused at a maintenance rate. Each monkey received intranasal midazolam (Versed™, Roche Pharma Inc, Monot, PR) at 0.2 mg and 0.4 mg/kg of body weight, using a 1 cc syringe without a needle, at randomly assigned separate treatment sessions with a minimum of 31 day intervals separating the experimental administrations. Approximately 2 cc of blood were obtained from an accessible vein at baseline, 5-, 10-, 20-, 30-, 45-, and 60-min intervals following the administration of the midazolam dosage. Each sample was coded and stored at -80°C for a maximum of 2 weeks, then submitted for mass spectrometric analysis. The laboratory technician was blinded to the dose levels of the sample being tested.

The experimental protocol of this study was approved by the Children's Hospital Animal Protection Committee. All statistical analyses were calculated using the Statview™ statistical package (Abacus Concepts, Berkley, CA).

Results

A rapid uptake was noted for both doses of midazolam. The mean plasma peak levels occurred at the 10-min interval for both doses used (Table). A significant difference between the 0.2 and the 0.4 mg/kg dosage was found at every time interval studied (P = 0.0002-0.05) with the exception of the 60-min measurement (P = 0.09). The difference between the two peak values was highly significant (P = 0.0002). All the monkeys recovered well without assistance.

Discussion

In a study of the pharmacokinetics of intranasal administration of midazolam in children prior to general anesthesia, Walbergh, et al. reported peak serum levels within 10 min. This study supports these findings with both doses used. The results of this investigation also showed unequivocally the high efficiency and consistency of the nasal route, even when higher doses of midazolam were used.

Dosage increase from 0.2 to 0.4 mg/kg results in a comparable rise in plasma levels of the drug, a phenomenon not usually encountered except with intravenous modes of administration. The similarity of this administration route to the submucosal route is evident from this investigation and others. Both bypass the portal circulation on the first progression through the circulatory system and peak serum levels appear within 10 min.
Dr. Sayany was senior dental resident, Children’s Hospital of Pittsburgh at the time of the study, and is currently in private practice of pediatric dentistry in Bricktown, New Jersey; Dr. Nazif is chief of dental services, Children’s Hospital of Pittsburgh; Mr. Burckart is professor of pharmacy, University of Pittsburgh; Dr. McKibben is Associate Professor of Pediatric Dentistry, Children’s Hospital of Pittsburgh; Mr. Hadeed is an undergraduate student, College of Literature, Science and Arts, University of Michigan, Ann Arbor, Michigan.


Pediatric Dentistry is on the Web!

Visit the American Academy of Pediatric Dentistry’s new web site at http://aapd.org to preview the abstracts of articles accepted for publication in Pediatric Dentistry months before they are published in the printed format. Abstracts will be online as soon as manuscripts are accepted and will include the date accepted and a target date for publication in the journal.

By using world wide web browser software, readers, authors and advertisers can access other journal information immediately, including:

- Instructions for contributors
- Advertising rates and deadlines
- Subscription forms
- Reference Manual passages

Also on the AAPD site are content areas for members, parents, and the media; helpful tips and free, downloadable software to help you best access our site; and links to hundreds of other sites including other dental and health care organizations and academic, federal, and regulatory institutions.

New Subscription Rates for 1997

Beginning in 1997 with Volume 19, Pediatric Dentistry nonmember subscription rates will be as follows:

<table>
<thead>
<tr>
<th></th>
<th>Domestic Address</th>
<th>Foreign Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual</td>
<td>$110</td>
<td>$145</td>
</tr>
<tr>
<td>Institution</td>
<td>$150</td>
<td>$185</td>
</tr>
</tbody>
</table>

As always, a subscription to Pediatric Dentistry is a benefit of membership in the American Academy of Pediatric Dentistry without additional charge.